Analyst Ratings For BioScrip Inc (NASDAQ:BIOS)
Today, BioScrip Inc (NASDAQ:BIOS) stock was downgraded by Stephens from Overweight to Equal Weight.
There are 3 Buy Ratings, 1 Hold Ratings, no Strong Buy Ratings, no Sell Ratings on the stock.
The current consensus rating on BioScrip Inc (NASDAQ:BIOS) is Buy with a consensus target price of $6.3333 per share, a potential 127.82% upside.
Some recent analyst ratings include
- 3/18/2019-BioScrip Inc (NASDAQ:BIOS) gets downgraded to Equal Weight by Stephens
- 12/12/2018-BioScrip Inc (NASDAQ:BIOS) has coverage initiated with a Buy rating and $5.00 price target
- 10/5/2018-BioScrip Inc (NASDAQ:BIOS) had its Buy rating reiterated by Barrington Research with a $4.00 price target
- 3/8/2018-BioScrip Inc (NASDAQ:BIOS) had its Buy rating reiterated by SunTrust Banks with a $3.25 price target
- 3/8/2018-BioScrip Inc (NASDAQ:BIOS) had its Buy rating reiterated by Craig Hallum with a $3.50 price target
- 8/10/2017-BioScrip Inc (NASDAQ:BIOS) had its Buy rating reiterated by Jefferies Financial Group with a $4.00 price target
- On 11/9/2017 Daniel E Greenleaf, CEO, bought 15,000 with an average share price of $2.03 per share and the total transaction amounting to $30,450.00.
- On 11/9/2017 Stephen Deitsch, CFO, bought 10,000 with an average share price of $2.03 per share and the total transaction amounting to $20,300.00.
- On 9/15/2017 Michael G Bronfein, Director, sold 27,000 with an average share price of $2.69 per share and the total transaction amounting to $72,630.00.
- On 9/7/2017 Coliseum Capital Management, L, Director, sold 2,846,941 with an average share price of $2.93 per share and the total transaction amounting to $8,341,537.13.
- On 8/17/2017 Coliseum Capital Management, L, Director, sold 886,478 with an average share price of $3.08 per share and the total transaction amounting to $2,730,352.24.
- On 11/11/2016 Jeffrey M Kreger, CFO, bought 10,000 with an average share price of $1.32 per share and the total transaction amounting to $13,200.00.
- On 11/10/2016 Daniel E Greenleaf, CEO, bought 16,000 with an average share price of $1.30 per share and the total transaction amounting to $20,800.00.
About BioScrip Inc (NASDAQ:BIOS)
BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.
Recent Trading Activity for BioScrip Inc (NASDAQ:BIOS)
Shares of BioScrip Inc closed the previous trading session at 2,78 −0,71 20,34 % with 3.77 shares trading hands.